- Serum admission levels of specific markers of NETosis (M±SD)_
| Marker | STEMI | NSTEMI | no-CCD | Control |
|---|---|---|---|---|
| MMP-8, ng/ml | 53.62±6.53 | 52.57±6.53 | 30.78±9.08 | 28.81±6.45 |
| p vs control | <0.001 | <0.001 | =0.0767 | |
| NE, ng/ml | 31.56±4.71 | 32.82±9.21 | 17.63±6.09 | 16.16±4.14 |
| p vs control | <0.001 | <0.001 | =0.0553 | |
| MPO, U/ml | 74.84±11.61 | 62.83±13.94 | 31.34±9.2 | 29.25±5.87 |
| p vs control | <0.001 | <0.001 | >0.05 | |
| E-selectin, ng/ml | 95.07±4.71 | 101.31±14.95 | 71.14±11.73 =0.0791 | 64.36±7.93 |
| p vs control | <0.001 | <0.001 |
- Indices of homogeneity of patient groups
| Index | STEMI | NSTEMI | no-CCD | p |
|---|---|---|---|---|
| Age (M±SD) | 67.2±3,4 | 68.1±3,2 | 66.8±3,9 | NS |
| Gender | ||||
| Male, n(%) | 48(60) | 43(53.7) | 46(57.5) | NS |
| Female, n(%) | 32(40) | 37(47.3) | 34(43.5) | NS |
| HTA, n(%) | 71(88.7) | 69(86.3) | 73(91.2) | NS |
| DM, n(%) | 26(32.5) | 23(28.7) | 25(31.2) | NS |
| Hypercholesterolemia, n(%) | 56(70) | 53(66.3) | 59(73.7) | NS |
| Smoking, n(%) | 14(17.5) | 13(16.2) | 18(22.5) | NS |
- Serum admission levels of oxidative stress markers (M±SD)_
| Marker | STEMI | NSTEMI | No-CCD | Control |
|---|---|---|---|---|
| MAD, μmol/L | 7.32±1.14 | 7.10±1.11 | 4.82±1.28 | 4.42±0.64 |
| p vs control | <0.001 | <0.001 | =0.0136 | |
| AOPP, μmol/L | 71.91±14.26 | 70.77±13.98 | 50.26±7.15 | 41.83±4.53 |
| p vs control | <0.001 | <0.001 | <0.001 | |
| NOX-2, pg/ml | 37.35±5.48 | 36.87±8.74 | 28.93±8.36 | 21.64±4.54 |
| p vs control | <0.001 | <0.001 | <0.001 |
- Serum admission levels of inflammation markers (M±SD)_
| Marker | STEMI | NSTEMI | no-CCD | Control |
|---|---|---|---|---|
| IL-1ß, pg/ml | 7.17±0,69 | 7.12±0,66 | 7.45±1,18 | 5.13±0.68 |
| p vs control | <0.001 | <0.001 | <0.001 | |
| IL-6, pg/ml | 7.34±0.79 | 7.15±1.55 | 4.53±1.75 | 4.36±0.64 |
| p vs control | <0.001 | <0.001 | =0.241 | |
| IL-6-R, pg/ml | 2.62±0.60 | 2.66±0.78 | 2.34±0.7 | 1.24±0.35 |
| p vs control | <0.001 | <0.001 | <0.001 | |
| IL-10, pg/ml | 3.71±0.74 | 3.98±1.72 | 7.35±1.8 | 7.77±0.98 |
| p vs control | <0.001 | <0.001 | =0.0529 | |
| TNF-a, pg/ml | 9.50±0.76 | 9.24±1.17 | 6.28±1.44 | 5.85±0.92 |
| p vs control | <0.001 | <0.001 | =0.024 | |
| Neopterin, nM/L | 4.89±0.86 | 4.59±0.86 | 3.72±0.95 | 3.48±0.72 |
| p vs control | <0.001 | <0.001 | 0.0547 | |
| hsPCR, mg/L | 7.90±0.74 | 7.85±0.87 | 3.93±1.39 | 1.45±0.41 |
| p vs control | <0.001 | <0.001 | <0.001 |
- Serum levels of endothelial dysfunction and re-endothelialization markers (M±SD)_
| Marker | STEMI | NSTEMI | No-CCD | Control |
|---|---|---|---|---|
| EMP (CD144+), | 328.09±37.58 | 282.97±59.86 | 158.44±55.69 | |
| Nr./ml | 148.58±10.46 | |||
| p vs control | <0.001 | <0.001 | =0.0892 | |
| Endocan, ng/ml | 3.58±0.61 | 3.55±0.70 | 1.52±0.57 | 1.27±0.41 |
| p vs control | <0.001 | <0.001 | =0.002 | |
| NO, μM/L | 50.65±7.77 | 52.66±0.78 | 51.49±11.27 | 74.21±8.47 |
| p vs control | <0.001 | <0.001 | <0.001 | |
| Apo 2, pg/ml | 3289.6±350.3 | 3367.9±153.2 | 2719.6±396.7 | 2146.1±122.9 |
| p vs control | <0.001 | <0.001 | <0.001 | |
| EPC, Nr./μL | 327.47±12.69 | 333.61±153.24 | 472.12±117.36 | 499.15±63.40 |
| p vs control | <0.001 | <0.001 | =0.0543 |
- Serum admission levels of neuroendocrine activity markers (M±SD)_
| Marker | STEMI | NSTEMI | no-CCD | Control |
|---|---|---|---|---|
| Neprilysin, | 1.99±0.82 | 2.07±0.67 | 0.94±0.36 | 0.49±0.38 |
| ng/ml | <0.001 | <0.001 | <0.001 | |
| Ang 1-7/Ang II, u.c. | 0.62±0.25 | 0.67±0.44 | 0.69±0.55 | 0.88±0.064 |
| p vs control | <0.001 | <0.001 | =0.0053 | |
| NT-pro-BNP, pg/ml | 402.74±182.80 | 514.12±99.01 | 151.23±45.16 | 142.44±17.25 |
| p vs control | <0.001 | <0.001 | >0.05 | |
| Adrenomedullin, pg/ml | 32.11±5.92 | 30.78±5.53 | 20.55±4.68 | 12.82±2.99 |
| p vs control | <0.001 | <0.001 | <0.001 | |
| Catestatin, ng/ml | 0.83±0.69 | 0.81±0.75 | 0.85±0.27 | 1.75±0.34 |
| p vs control | <0.001 | <0.001 | <0.001 |
- Serum admission levels of hemostasis markers (M±SD)_
| Marker | STEMI | NSTEMI | no-CCD | Control |
|---|---|---|---|---|
| PMV, CD62P, 1/μL | 319.08±84.19 | 304.94±92.03 | 175.46±67.77 | 161.37±16.85 |
| p vs control | <0.001 | <0.001 | =0.059 | |
| FM, mg/ml | 8.41±1.03 | 8.42±2.07 | 4.75±0.94 | 4.54±0.63 |
| p vs control | <0.001 | <0.001 | =0.0716 | |
| vWillebrand/ | 2.78±1.46 | 2.34±0.92 | 1.89±0.59 | |
| ADAMTS13, u.c. | 1.26±0.38 | |||
| p vs control | <0.001 | <0.001 | <0.001 |
- Serum admission levels of atherogenicity markers (M±SD)_
| Marker | STEMI | NSTEMI | no-CCD | Control |
|---|---|---|---|---|
| Paraoxonase 1, | 241.37±40.74 | 237.30±40.56 | 314.32±52.38 | |
| nM/mL | 421.55±25.14 | |||
| p vs control | <0.001 | <0.001 | <0.001 | |
| LP(a), mg/dl | 6.69±2.95 | 6.74±2.81 | 5.18±2.33 | 2.94±0.95 |
| p vs control | <0.001 | <0.001 | <0.001 | |
| oxi-HDL, u.c. | 2.78±0.76 | 2.73±0.57 | 2.47±0.9 | 1±0.15 |
| p vs control | <0.001 | <0.001 | <0.001 |
- Serum admission levels of cardiovascular remodeling markers (M±SD)_
| Marker | STEMI | NSTEMI | no-CCD | Control |
|---|---|---|---|---|
| GDF-15, ng/ml | 2.67±0.81 | 2.86±0,82 | 2.45±0.75 | 1.29±0.44 |
| p vs control | <0.001 | <0.001 | <0,001 | |
| FGF-21, pg/ml | 92,21±9,94 | 91.66±11.54 | 66.36±8.09 | 64.29±6.39 |
| p vs control | <0.001 | <0.001 | =0.0532 | |
| TGF-ß, ng/ml | 8.15±1.13 | 7.31±1.12 | 5,11±1,36 | 4.85±0.87 |
| p vs control | <0.001 | <0.001 | =0.1 | |
| Syndecan 1, ng/ml | 261.50±36.17 | 246.74±36.17 | 128.25±15.81 | 125.86±7.39 |
| p vs control | <0.001 | <0.001 | =0.0601 | |
| Galectine-3, ng/ml | 7.66±1.78 | 6.71±2.01 | 3.81±1.28 | 3.52±0.78 |
| p vs control | <0.001 | <0.001 | =0.05789 | |
| MMP-2, ng/ml | 4.92±1.30 | 4.61±1.42 | 3.81±1.28 | 25.17±0.77 |
| p vs control | <0.001 | <0.001 | =0.0511 | |
| MMP-9, ng/ml | 21.73±3.79 | 22.56±4.86 | 16.35±7.87 | 14.71±2.64 |
| p vs control | <0.001 | <0.001 | =0.0614 |